Free Trial
→ Trump's gold order: the announcement they won't put on the front page (From Reagan Gold Group) (Ad)tc pixel
NASDAQ:SNTI

Senti Biosciences Q1 2026 Earnings Report

Senti Biosciences logo
$1.00 +0.03 (+3.05%)
As of 03:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Senti Biosciences EPS Results

Actual EPS
-$0.14
Consensus EPS
-$0.36
Beat/Miss
Beat by +$0.22
One Year Ago EPS
N/A

Senti Biosciences Revenue Results

Actual Revenue
$0.02 million
Expected Revenue
$0.02 million
Beat/Miss
Missed by -$5.00 thousand
YoY Revenue Growth
N/A

Senti Biosciences Announcement Details

Quarter
Q1 2026
Date
5/14/2026
Time
Before Market Opens
Conference Call Date
Thursday, May 14, 2026
Conference Call Time
9:00AM ET

Upcoming Earnings

Senti Biosciences' Q2 2026 earnings is estimated for Thursday, August 6, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 7, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Senti Biosciences' Q1 2026 Press ReleasePress Release
(8-K)
Senti Biosciences' Q1 2026 Quarterly reportQuarterly report
(10-Q)

Senti Biosciences Earnings Headlines

Senti Biosciences Faces Severe Refinancing and Liquidity Risks from Costly Note Structure
May 16, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/senti-biosciences-faces-severe-refinancing-and-liquidity-risks-from-costly-note-structure?utm_source=marketbeat.com&utm_medium=referral
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important ...
May 14, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/senti-biosciences-holdings-announces-positive-fda-rmat-meeting-on-registrational-clinical-and-cmc-strategy-for-senti-202-in-relapsed-refractory-aml-along-with-important-efficacy-and-durability-1036155933
SpaceX is offering you shares. Don't take them.
SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. But at a $1.75 trillion valuation and 266 times earnings, early institutional holders may be looking for someone to sell to. Dylan Jovine has identified a small company in Musk's supply chain that builds the power infrastructure behind Colossus - still trading at a fraction of its potential value. No IPO allocation required.tc pixel
June 4 at 1:00 AM  |  Behind the Markets (Ad)
Senti Biosciences Secures Up to $40 Million Financing and FDA Endorsement for SENTI-202 in Relapsed/Refractory Acute Myeloid Leukemia
May 14, 2026  |  quiverquant.comQ
Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase
May 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/14/3294967/0/en/senti-biosciences-holdings-reports-first-quarter-2026-financial-results-and-highlights-advancement-of-senti-202-program-into-pivotal-phase.html
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program
May 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/14/3294958/0/en/senti-biosciences-holdings-announces-positive-fda-rmat-meeting-on-registrational-clinical-and-cmc-strategy-for-senti-202-in-relapsed-refractory-aml-along-with-important-efficacy-an.html
See More Senti Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Senti Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Senti Biosciences and other key companies, straight to your email.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release. These platforms support a diverse pipeline of preclinical cell therapy programs targeting solid tumors, hematologic malignancies and autoimmune disorders.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Senti Biosciences completed its initial public offering in June 2021 and is listed on the Nasdaq exchange. The company collaborates with academic and industry partners to advance its research and expand its proprietary platform capabilities.

Senti is led by a management team combining expertise in synthetic biology, immunology and biotechnology development. The leadership team includes seasoned industry executives and academic scientists committed to translating circuit-based cell therapies into clinical applications worldwide.

View Senti Biosciences Profile
Earnings Tools